Tacrolimus
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Transplantation
Conditions
Kidney Transplantation
Trial Timeline
Mar 5, 2015 → Sep 30, 2022
NCT ID
NCT02555787About Tacrolimus
Tacrolimus is a pre-clinical stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT02555787. Target conditions include Kidney Transplantation.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplantation were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189761 | Phase 2 | Completed |
| NCT00293930 | Phase 3 | Completed |
| NCT00189787 | Phase 2 | Completed |
| NCT00189722 | Phase 2 | Completed |
| NCT03465969 | Approved | Completed |
| NCT02555787 | Pre-clinical | Completed |
| NCT02147938 | Pre-clinical | Completed |
| NCT02143479 | Pre-clinical | Completed |
| NCT02159651 | Pre-clinical | Completed |
| NCT02057484 | Pre-clinical | Completed |
| NCT02377609 | Pre-clinical | Terminated |
| NCT01745159 | Approved | Completed |
| NCT01511003 | Approved | Completed |
| NCT01316133 | Approved | Terminated |
| NCT01410162 | Approved | Completed |
| NCT02963103 | Approved | Terminated |
| NCT01224041 | Approved | Completed |
| NCT01224418 | Approved | Completed |
| NCT00504348 | Phase 2/3 | Completed |
| NCT01410747 | Pre-clinical | Completed |
Competing Products
20 competing products in Kidney Transplantation